• -->


The AC Forum Lunch & Learn Webinar Series covers important and timely topics in anticoagulation care. The webinars are presented each month by international experts, and moderated by a multidisciplinary team of AC Forum board members. Each one hour webinar is presented free of charge and is open to all healthcare professionals. All webinars require pre-registration.

Register for Upcoming Webinars

January Webinar: Antiphospholipid Syndrome: DOACs vs. Warfarin
Wednesday, January 9, 2019 12:00 PM ET

Guest Speakers:
David Garcia, MD
Vittorio Pengo, MD

This webinar will use a case-based approach to review diagnosis and management of Antiphospholipid Syndrome and discuss the results of the TRAPS study. Combining highlights from two recent articles on APS, Diagnosis and Management of the Antiphospholipid Syndrome and Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome this session will provide a practical overview of this complicated topic. Lead authors Dr. David Garcia and Dr. Vittorio Pengo will join our panel of AC Forum experts for this webinar.

David Garcia, M.D., is associate medical director of Anti-Thrombotic Therapy at UW Medical Center and a UW professor of Hematology and Medicine. Dr. Garcia is a member of the board of directors for a number of organizations including the North American Society of Thrombosis and Hemostasis, the Thrombosis and Hemostasis Societies of North America and the Anticoagulation Forum. Dr. Garcia’s clinical and research interests include all hematologic disorders, development of novel oral anticoagulants, cancer-associated thrombosis and the management of anticoagulant-associated bleeding.

Vittorio Pengo, MD is a professor of Cardiovascular Medicine in the Department of Cardiac Thoracic and Vascular Sciences, and Director of Thrombosis Center at the University of Padova School of Medicine in Padova, Italy. His clinical interests are in primary/secondary prevention and treatment of venous and arterial thromboembolism and his research is focused on the pathophysiology and treatment of thrombosis. He has authored over 300 original papers in international journals.

Webinar Archive

All webinars are recorded and can be viewed below.

Evidence-Based Best Practices for Outpatient Management of Warfarin
December 6, 2018
Adam Rose, MD, MSc, FRCPC
Role of Direct Oral Anticoagulants in the Treatment of Cancer-Associated VTE: Guidance from the SSC of the ISTH
November 6, 2018
Dr. Marc Carrier, MD, MSc, FRCPC
Vascular Protection: Preventing Thrombotic Complications of VTE and PAD
October 11, 2018
Geoff Barnes, MD; Scott Damrauer, MD
Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT Trial)
July 18, 2018
Suresh Vedantham, MD
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty
June 6, 2018
2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants
May 9, 2018
Adam Cuker, MD
Renal Function Considerations for Stroke Prevention in Atrial Fibrillation
March 28, 2018
John Fanikos, RPh, MBA; Paul Dobesh, PharmD, FCCP, BCPS; Curt Mahan, PharmD
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease (COMPASS Trail)
February 8, 2018
John Eikelboom, MB, BS
HOKUSAI VTE Cancer Trial: Edoxaban for the Treatment of Cancer-Associated VTE
January 9, 2018
David Garcia, MD
Using Clinical Order Sets to Integrate Quality Standards into Point of Care
December 15, 2017
Scott Kaatz, DO, MSc, FACP, SFHM; Geoff Barnes, MD, MSc; Eva Kline-Rogers, MS, NP, AACP; Stacy Ellsworth, RN, MSN, CCRC
A Multifaceted Intervention to Improve Treatment with Oral Anticoagulants in Atrial Fibrillation (IMPACT-AF): An International, Cluster-Randomised Trial
November 15, 2017
Renato D. Lopes, MD, MHS, PhD
Re-Circuit Trial
October 17, 2017
Edward Gerstenfeld, MD
Extended Thrombo-prophylaxis with Betrixaban in Acutely Ill Medical Patients
August 16, 2017
C. Michael Gibson, MD
Prevention of Thromboembolic Complications in Patients with Superficial-Vein Thrombosis Given Rivaroxaban or Fondaparinux
June 20, 2017
Jan Beyer-Westendorf, MD
Einstein Choice Trial
May 23, 2017
Jeff Weitz, MD, PhD
Ticagrelor vs. Clopidogrel in Symptomatic Peripheral Artery Disease
March 28, 2017
William Hiatt, MD
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI
February 28, 2017
C. Michael Gibson, MD
Anticoagulant Therapy for Symptomatic Calf DVT (CACTUS)
January 11, 2017
Marc Carrier, MD, MSc; Gregoire Le Gal, MD, PhD
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
December 15, 2016
Peter A. Noseworthy, MD; Xiaoxi Yao, PhD, MPH, MS
Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy
October 25, 2016
Jean M. Connors, MD; Megan E. Barra, PharmD; John Fanikos, RPh, MBA
Reducing the Hospital Burden of HIT: Impact of an Avoid-Heparin Program
September 29, 2016
William Geerts, MD
Guidance for the Practical Management of the Heparin Anticoagulants in the Treatment of VTE
August 17, 2016
Maureen Smythe, PharmD; Paul Dobesh, PharmD; Diane Wirth, ANP; Adam Cuker, MD and Jack Ansell, MD
NATF Atrial Fibrillation Consensus Document
June 30, 2016
Christian T. Ruff, MD, MPH
Effect of Body Weight on the Efficacy and Safety of the DOACs in VTE
May 12, 2016
Francesco Dentali, MD
Guidance for the Evaluation and Treatment of Hereditary and Acquired Thrombophilia
March 30, 2016
Scott Stevens, MD
Guidance for the Prevention and Treatment of Cancer-Associated VTE
March 3, 2016
David Garcia, MD; Jack Ansell, MD
Guidance for the Practical Management of the Direct Oral Anticoagulants (DOACs) in VTE Treatment
February 9, 2016
Allison Burnett, PharmD; Sara Vazquez, PharmD; Jack Ansell, MD
Guidance for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism
January 20, 2016
Jack Ansell, MD; Michael Streiff, MD; Mark Crowther, MD
The Changing Characteristics of Atrial Fibrillation Patients Treated with Warfarin
December 1, 2015
Eva Kline-Rogers, NP; Geoff Barnes, MD; Scott Kaatz, DO
Clinical Monitoring of DOACs: "Site-Level Variation in and Practices Associated with Dabigatran Adherence"
October 20, 2015
Supriya Shore, MD
Idarucizumab for Dabigatran Reversal
September 30, 2015
Charles Pollack, Jr., MD; Jeffrey Weitz, MD
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
August 25, 2015
James Douketis, MD; David Garcia, MD; Scott Kaatz, DO
Clinical Characteristics & Outcomes with Rivaroxaban vs. Warfarin in Patients with NVAF but Underlying Native Mitral and Aortic Valve Disease Participating in the ROCKET AF Trial
June 16, 2015
Richard C. Becker, MD
Amiodarone, Anticoagulation, and Clinical Events in Patients with Atrial Fibrillation: Insights from the ARISTOTLE Trial
May 14, 2015
Christopher Granger, MD; Renato Lopes, MD, PhD
Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients with Atrial Fibrillation
March 17, 2015
Benjamin Steinberg, MD; Jack Ansell, MD
An Evaluation of the Potential Drug Interaction Between Warfarin and Levothyroxine
February 19, 2015
John R. Horn, PharmD; Michele D. Wood, PharmD; Nathan Clark, PharmD; Daniel M. Witt, PharmD
Edoxaban vs Warfarin in Patients with Atrial Fibrillation
January 20, 2015
Robert Giugliano, MD; Christian Ruff, MD, MPH
National Assessment of Warfarin Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation
November 20, 2014
Jeffrey S. Dlott, MD
Patient Webinar - DVT and PE Discussion in Honor of World Thrombosis Day
October 16, 2014
Stephan Moll, MD
Antibiotic Interaction with Warfarin in the Ambulatory Setting
September 18, 2014
Nathan Clark, PharmD; Adam Cuker, MD; Scott Kaatz, DO, MSc
A Review of RE-COVER I and II: FDA Approves use of Dabigatran for treatment of acute VTE
June 19, 2014
Samuel Z. Goldhaber, MD; Adam Cuker, MD; Scott Kaatz, DO, MSc
Compression Stockings to Prevent Post-thrombotic Syndrome: A Randomized Placebo-controlled Trial
May 15, 2014
Susan R. Kahn, MD, MSc
Limited English proficient patients and time spent in therapeutic range in a warfarin anticoagulation clinic
April 16, 2014
Jenny Lopez, MD, MPH, MDiv; Lynn B. Oertel, MS, ANP; Scott Kaatz, DO, MSc
Anticoagulation Centers of Excellence: A Case-Based Demonstration
March 20, 2014
Daniel M. Witt, PharmD, FCCP, BCPS, CACP; Arthur Allen, PharmD, CACP; Allison Burnett, PharmD, PhC, CACP; Elaine Whalen, MBA
CLOTS3 Trial: AC Forum and Thrombosis Canada
September 19, 2013
Professor Martin Dennis
FDA Postmarketing Report on Dabigatran
July 18, 2013
Mary Ross Southworth, PharmD; Marsha E. Reichman, PhD; Ellis F. Unger, MD